Associated Papers
Sustained complete response to first-line immunochemotherapy for highly aggressive TP53/MDM2-mutated upper tract urothelial carcinoma with ERBB2 mutations, luminal immune-infiltrated contexture, and non-mesenchymal state: a case report and literature review.
Xu T et al.
Frontiers in Oncology, 2023
37427135 (PubMed )
Supplement: DataSheet_1.pdf
Select a paper to view details